LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

Search

Voyager Therapeutics Inc

Closed

4.26

Overview

Share price change

24h

Current

Min

4.06

Max

4.33

Key metrics

By Trading Economics

Income

-2.4M

-33M

Sales

-1.3M

5.2M

P/E

Sector Avg

6.415

35.733

Profit margin

-641.962

Employees

172

EBITDA

-1.9M

-36M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+286.32% upside

Dividends

By Dow Jones

Next Earnings

11 lis 2025

Market Stats

By TradingEconomics

Market Cap

8.7M

186M

Previous open

4.26

Previous close

4.26

Technical Score

By Trading Central

Confidence

Bearish Evidence

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 paź 2024, 21:31 UTC

Top News

AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

286.32% upside

12 Months Forecast

Average 16.38 USD  286.32%

High 30 USD

Low 8 USD

Based on 10 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
help-icon Live chat